Solara Active Pharma Sciences Q4 FY26 Earnings Call Transcript Released
Solara Active Pharma Sciences released its Q4 FY26 earnings call transcript. The company reported its highest revenue, gross margins, and EBITDA in 8 quarters, with a 12% Q-o-Q revenue growth and 65% EBITDA growth. Strategic options for the ibuprofen business are being evaluated, with a resolution expected in two quarters. Debt was reduced by ₹158 crore in FY26.
The announcement provides a detailed update on financial performance and strategic decisions regarding the ibuprofen business. While the positive results are encouraging, the ongoing evaluation of strategic options for a significant business segment and the long-term timeline for new product revenue realization suggest a medium-term impact.
The company reported strong financial performance in Q4 FY26, with record revenues and EBITDA over the last 8 quarters, driven by its base business. Despite challenges in the ibuprofen segment, the overall positive results and clear strategic direction for growth contribute to a positive sentiment.
Solara Active Pharma Sciences Limited has released the transcript of its earnings conference call for the quarter and year ended March 31, 2026. The call, which was conducted on Friday, May 15, 2026, followed a Board of Directors meeting. During the call, the management highlighted that Q4 FY26 demonstrated strong sequential growth with a 12% increase in revenue and a 65% increase in EBITDA quarter-on-quarter. The company achieved its highest revenue, gross margins, and EBITDA in the previous 8 quarters. The base business, operating at a 26% EBITDA margin and 54% gross margin, was the primary driver of this performance, reinforcing the company's objective to pivot towards sustainable, profitable, and reliable growth.
Despite facing persistent headwinds in the ibuprofen business, which recorded negative EBITDA, the company has appointed bankers to evaluate strategic options for this segment, with an expected resolution in the next two quarters. Consequently, the carve-out of polymers in the CRAMS business has been put on hold until H1 '27. The company reported Q4 FY26 revenue of ₹392 crore, with gross margins at 47% (₹184 crore) and EBITDA at ₹61 crore. Operating costs remained flat quarter-on-quarter. Developed markets continued to contribute 75% of overall sales.
Solara Active Pharma Sciences has reduced its debt by approximately ₹158 crore during FY26, a 21% reduction, with plans to further reduce it to around ₹503 crore by the end of May '26, primarily through rights issue proceeds. The management indicated that while the ibuprofen business is being divested, the base business, catalogue generics, and polymer APIs will be the focus for growth. The company has a healthy order book and approximately 30% of its capacity is available for utilization. While R&D spending has been significant in the past, a renewed focus on commercially viable products is underway, with plans to file four to five DMFs annually, expecting revenue impact from FY29-FY30 onwards. The company aims to become debt-free by FY29.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.